{
  "success": true,
  "command": "SRPT EQ DES",
  "data": {
    "timestamp": "2025-10-01T01:34:16.156850Z",
    "window_id": "3730-window",
    "ticker": "SRPT US",
    "company_info": {
      "company_name": "Sarepta Therapeutics Inc",
      "asset_class": "EQ",
      "logo_url": "https://api.twelvedata.com/logo/sarepta.com",
      "website": "https://sarepta.com/",
      "address": "215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142",
      "ceo": "CEO: MR. DOUGLAS S. INGRAM ESQ., J.D."
    },
    "description": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Childrens Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.",
    "eps_estimates": {"Q4, Dec 25": "-0.85", "FY25, Dec 25": "-2.27", "FY26, Dec 26": "3.25"},
    "analyst_ratings": [
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Outperform",
        "Target": "$50→$50",
        "Date": "9/22/2025 12:19"
      },
      {
        "Firm": "Guggenheim",
        "Analyst": "Debjit Chattopadhyay",
        "Rating": "Buy",
        "Target": "$22→$22",
        "Date": "9/15/2025 13:41"
      },
      {
        "Firm": "Leerink Partners",
        "Analyst": "Joseph Schwartz",
        "Rating": "Market Perform",
        "Target": "$12→$15",
        "Date": "9/9/2025 19:00"
      },
      {
        "Firm": "HC Wainwright & Co.",
        "Analyst": "Mitchell S. Kapoor",
        "Rating": "Sell",
        "Target": "$5→$5",
        "Date": "8/25/2025 16:36"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Target": "$17→$16",
        "Date": "8/21/2025 22:45"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Target": "$10→$17",
        "Date": "8/20/2025 17:45"
      },
      {
        "Firm": "Deutsche Bank",
        "Analyst": "David Hoang",
        "Rating": "Sell",
        "Target": "$6→$12",
        "Date": "8/15/2025 22:39"
      },
      {
        "Firm": "Wells Fargo",
        "Analyst": "Yanan Zhu",
        "Rating": "Overweight",
        "Target": "$48→$50",
        "Date": "8/7/2025 19:51"
      },
      {
        "Firm": "Goldman Sachs",
        "Analyst": "Salveen Richter",
        "Rating": "Neutral",
        "Target": "$10→$19",
        "Date": "8/7/2025 22:38"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Target": "$10→$22",
        "Date": "7/30/2025 18:05"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Target": "$10→$22",
        "Date": "7/29/2025 22:56"
      },
      {
        "Firm": "Bernstein",
        "Analyst": "William Pickering",
        "Rating": "Market Perform",
        "Target": "",
        "Date": "7/29/2025 20:30"
      },
      {
        "Firm": "JP Morgan",
        "Analyst": "Anupam Rama",
        "Rating": "Neutral",
        "Target": "",
        "Date": "7/29/2025 15:55"
      },
      {
        "Firm": "Piper Sandler",
        "Analyst": "Biren Amin",
        "Rating": "Neutral",
        "Target": "$11→$15",
        "Date": "7/29/2025 17:09"
      },
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Market Perform",
        "Target": "$25→$50",
        "Date": "7/29/2025 19:32"
      },
      {
        "Firm": "Oppenheimer",
        "Analyst": "Hartaj Singh",
        "Rating": "Outperform",
        "Target": "$30→$37",
        "Date": "7/29/2025 16:15"
      },
      {
        "Firm": "Morgan Stanley",
        "Analyst": "Matthew Harrison",
        "Rating": "Equal-Weight",
        "Target": "$15→$20",
        "Date": "7/29/2025 16:58"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Underweight",
        "Target": "$18→$10",
        "Date": "7/27/2025 23:02"
      },
      {
        "Firm": "Wells Fargo",
        "Analyst": "Yanan Zhu",
        "Rating": "Overweight",
        "Target": "$65→$48",
        "Date": "7/24/2025 18:30"
      },
      {
        "Firm": "Citigroup",
        "Analyst": "Yigal Nochomovitz",
        "Rating": "Sell",
        "Target": "",
        "Date": "7/24/2025 15:33"
      },
      {
        "Firm": "Jefferies",
        "Analyst": "Andrew Tsai",
        "Rating": "Buy",
        "Target": "$40→$35",
        "Date": "7/24/2025 21:13"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Target": "$20→$10",
        "Date": "7/23/2025 16:11"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Target": "$32→$18",
        "Date": "7/22/2025 15:45"
      },
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Market Perform",
        "Target": "$50→$25",
        "Date": "7/22/2025 21:06"
      },
      {
        "Firm": "Piper Sandler",
        "Analyst": "Biren Amin",
        "Rating": "Neutral",
        "Target": "$18→$11",
        "Date": "7/22/2025 18:49"
      }
    ],
    "snapshot": {
      "Exchange": "XNGS",
      "Currency": "USD",
      "Float": "87.6M",
      "Employees": "1,372",
      "Insiders": "4.66%",
      "Institutions": "82.23%",
      "P/Sales": "0.77",
      "P/Book": "1.32",
      "EV/EBITDA": "58.74",
      "EV/R": "0.95",
      "EV": "2.4B",
      "Trl P/E": "19.98x",
      "Fwd P/E": "1.60x",
      "Trl Yld": "-",
      "Fwd Yld": "-",
      "5Y Avg Yld": "-",
      "Payout R": "-",
      "Ex Div Date": "-",
      "Div Date": "-",
      "Beta": "0.49",
      "Short": "20.3M",
      "Short R": "3.59"
    }
  }
}